Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

OBJECTIVE: Bone mineral density (BMD) loss, a risk factor for osteoporosis, has been attributed to HIV infection and antiretroviral therapy (ART), including regimens containing tenofovir disoproxil fumarate. DESIGN: Study 202094 is an open-label, parallel-group, sub-study of the phase III SWORD-1 an...

Descripción completa

Detalles Bibliográficos
Autores principales: McComsey, Grace A., Lupo, Sergio, Parks, David, Poggio, Mónica Coronado, De Wet, Joseph, Kahl, Lesley P., Angelis, Kostas, Wynne, Brian, Vandermeulen, Kati, Gartland, Martin, Cupo, Michael, Aboud, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802259/
https://www.ncbi.nlm.nih.gov/pubmed/29239893
http://dx.doi.org/10.1097/QAD.0000000000001725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802259/
https://www.ncbi.nlm.nih.gov/pubmed/29239893
http://dx.doi.org/10.1097/QAD.0000000000001725

Ejemplares similares